When President Donald Trump considered a range of options about regulating the use of fetal tissue in medical research, he made a simple political calculation. A ban would solidify support from religious anti-abortion advocates, while there would be no political cost to cutting off research that contributes to biomedical progress.
Trump bet correctly on the indifference and timidity of the biopharma industry.
Biopharma companies, the organizations that represent them, and corporate leaders have obligations to speak out on the issue.
Unlike other political controversies biotech leaders have addressed over the last two years, like immigration and freedom of the press, fetal tissue research uniquely affects their companies. And biopharma executives can contribute expertise to the debate that other corporate leaders lack.